期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 63, 期 4, 页码 1612-1623出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.9b01423
关键词
-
资金
- Forma Therapeutics, Inc.
Inhibition of mutant IDH1 is being evaluated clinically as a treatment option for oncology. Here we describe the structure-based design and optimization of quinoline lead compounds to identify FT-2102, a potent, orally bioavailable, brain penetrant, and selective mIDH1 inhibitor. FT-2102 has excellent ADME/PK properties and reduces 2-hydroxyglutarate levels in an mIDH1 xenograft tumor model. This compound has been selected as a candidate for clinical development in hematologic malignancies, solid tumors, and gliomas with mIDH1.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据